Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).
Joël MercierMassimo BaniAnny-Odile ColsonMassimiliano GermaniMarianna LallaChristophe PlissonMickael HuibanGraham SearleFrançois-Xavier MathyRichard NichollChristian OtoulJohan Willem SmitVanja van AschMichel WagneurRalph Paul MaguirePublished in: Molecular imaging and biology (2023)
C]minzasolmin was used in the phase 1 study, which demonstrated that minzasolmin readily crossed the blood-brain barrier and was well distributed throughout the brain. Safety and pharmacokinetic findings were consistent with previous early-phase studies (such as UP0077, NCT04875962).
Keyphrases
- pet imaging
- resting state
- white matter
- positron emission tomography
- case control
- computed tomography
- functional connectivity
- cerebral ischemia
- open label
- pet ct
- randomized controlled trial
- clinical trial
- multiple sclerosis
- stem cells
- mesenchymal stem cells
- blood brain barrier
- subarachnoid hemorrhage
- study protocol
- double blind
- placebo controlled